Leslie Hudson, PhD, served as the CEO of Sarepta Therapeutics, Inc. from July 2008 until April 2010. With a PhD in Molecular Biology, he helped steer the company through key developments in biotechnology, particularly in RNA therapeutics aimed at genetic...

Leslie Hudson, PhD, served as the CEO of Sarepta Therapeutics, Inc. from July 2008 until April 2010. With a PhD in Molecular Biology, he helped steer the company through key developments in biotechnology, particularly in RNA therapeutics aimed at genetic diseases. Hudson left a mark by overseeing substantial projects that involved innovative approaches for treating conditions like Duchenne muscular dystrophy. His tenure was cut short when he resigned, which the company treated as an involuntary termination. During his time, he also faced significant challenges, being ineligible for performance bonuses in his final year due to his departure. In his earlier years, Hudson held several senior roles, including CEO of DOV Pharmaceutical and Vice Provost at the University of Pennsylvania, expanding his expertise in leadership within the biotech sector. Known for his strategic insights, Hudson's time at Sarepta shaped the company's vision and direction during a pivotal period.

Quick Links

1. Rivals

2. Holdings

3. Insider Trading

4. Compensation History

5. Other Sarepta Therapeutics, Inc. CEOs

S

Leslie Hudson, PhD

Ex-CEO of Sarepta Therapeutics, Inc.

Education

PhD in Molecular Biology

Field of Expertise

Healthcare & Life Sciences - Biotechnology

Sector of Economy

Healthcare

Born

September 17, 1957 - 67 years ago

CEO of Sarepta Therapeutics, Inc. for

1 year 8 months (Jul 2008 - Apr 2010)

Previous Experience

CEO of AVI BioPharma, Inc.

Rivals

Competitors/colleagues of Leslie Hudson, PhD

Holdings

See how much did Leslie Hudson, PhD make over time.

During his time at Sarepta, Leslie Hudson held significant stock options, including grants for up to 600,000 shares in 2010. His wealth in company stock saw fluctuations during his tenure, highlighting an interesting rollercoaster as the company navigated through challenging...

During his time at Sarepta, Leslie Hudson held significant stock options, including grants for up to 600,000 shares in 2010. His wealth in company stock saw fluctuations during his tenure, highlighting an interesting rollercoaster as the company navigated through challenging phases. Notably, Hudson had several big increases in his insider trading value leading up to his resignation, showing his confidence in the company at the time. In the months leading up to his departure, his various holdings fluctuated, demonstrating his strong commitment to the company's growth and stability. However, upon resigning, these potential earnings became uncertain, reflecting the challenges faced in executive positions when changes in leadership occur. Investors saw changes in stock performance as the transition unfolded, a common occurrence in the biotech sector where leadership can significantly influence market perception.

Insider Trading

See recent insider trades of Leslie Hudson, PhD.

No insider trades found for this CEO.

Compensation History

See how much did Leslie Hudson, PhD make over time.

In 2010, Leslie Hudson's total compensation was $932,871. His base salary was $494,400, with no bonus due to his resignation in April. He had significant stock options granted, mostly unvested when he left. This compensation package was designed to attract and retain executives during a crucial time for the company, but Hudson's unexpected departure highlighted the risks associated with leadership roles in high-stakes industries. Prior to this, in 2009, Hudson received a total compensation of $1,141,869, which included a notable performance bonus tied closely to corporate achievements. Although his time with Sarepta was marked by both challenges and opportunities, Hudson's legacy in the biotech space reflects the constant evolution and risks involved in leadership.

Year

2010

Total Compensation

$932.87K

Salary

$494.40K

Board Justification

The compensation philosophy aims to attract and retain senior executive management, motivate performance towards defined goals, and align long-term interests with shareholders.

Bonus

$0.00

Board Justification

Dr. Hudson was ineligible for a 2010 performance bonus due to his resignation in April 2010.

Other

$438.47K

Board Justification

Other compensation includes temporary living expenses, financial services, and cash severance costs.

Restricted Stock

$0.00(0 common stock)

Board Justification

No stock grants were vested in 2010 as Dr. Hudson resigned in April 2010.

Performance Metrics

Dr. Hudson's performance metrics were tied to corporate objectives, but he was ineligible for bonuses due to resignation.

Other Sarepta Therapeutics, Inc. CEOs

Here are other CEOs of Sarepta Therapeutics, Inc.

J. David Boyle II

Ex-CEO of Sarepta Therapeutics, Inc.

April 2010 - July 2011